Investec Bank Plc has submitted a Form 8.5 regulatory dealing disclosure relating to Advanced Medical Solutions Group Plc (AMS.L) under Rule 8.5 of the Takeover Code.
The disclosure, filed on 3rd September 2026, covers dealings undertaken by Investec in its capacity as an exempt principal trader with recognised intermediary status.
Investec Bank Plc serves as Advisor and Joint Broker to Advanced Medical Solutions Group Plc, establishing its connected status to the offer party named in the filing.
The dealings in question were carried out on 2nd September 2026, involving ordinary shares in Advanced Medical Solutions Group Plc across both purchase and sale transactions.
On the purchase side, Investec acquired 182,275 ordinary shares, with prices ranging from a low of 280.75p to a high of 281p per unit.
On the sales side, Investec sold a significantly larger volume of 855,455 ordinary shares, with prices ranging from 280.75p to 281.5p per unit.
No cash-settled derivative transactions, stock-settled derivative transactions, or options were reported as part of this regulatory disclosure filing.
Investec confirmed that no indemnity or option arrangements exist that could serve as an inducement to deal or refrain from dealing in relation to the offer.
The firm also stated that no agreements, arrangements, or understandings exist relating to voting rights under any option or future acquisition and disposal of relevant securities tied to any derivative.
The disclosure contact listed in the filing is Abhishek Gawde, reachable via telephone for any further enquiries related to this regulatory submission.
Public disclosures of this nature are required under Rule 8 of the Takeover Code and must be submitted to a Regulatory Information Service in accordance with panel guidelines.
The Panel’s Market Surveillance Unit remains available for consultation regarding dealing disclosure requirements under the Code for any parties seeking further regulatory clarity.
